OBJECTIVES: To estimate the economic impact of managing chemotherapy patients at risk of neutropenia and eligible to receive Granulocyte-Colony Stimulating Factor (G-CSF) with lipegfilgatrim (LONQUEX,  a new long-acting G-CSF) rather than pegfilgastrim in Spain.  METHODS: Both the BIA and CMA were conducted from the Spanish-payer’s perspective: they included direct drug cost, administration, neutropenic events and adverse event costs, but did not consider indirect costs. The drug acquisition cost of lipegfilgatrim used in the model was based on the anticipated price of lipegfilgatrim at the time of launch in Spain.  All costs were expressed in EUROS-2013. A range of sensitivity, scenario and threshold analyses were performed. An additional analysis was performed within the BIA to explore the trend towards fewer dose modifications in the lipegfilgatrim arm of the XM22-03 trial.    RESULTS: The CMA shows that treating a patient with lipegfilgatrim instead of pegfilgrastim resulted in a cost saving of 650,06€. At the population level, the BIA predicts that cost savings could range from 113.166€ in year 1 to 678.995€ in year 5, totaling to 2.489.648€ over five years. Furthermore, the BIA shows a potential to avoid 50 dose modifications with the use of lipegfilgatrim instead of pegfilgrastim. The model is most sensitive to the cost of pegfilgrastim and lipegfilgatrim, but results are robust, with the model estimating cost savings over a wide range of inputs. When the trend towards decreased NE and increased AE with lipegfilgatrim  vs pegfilgrastim reported in the XM22-03 trial is explored, cost savings was about 30% compared to the default scenario, reaching 3.208.619 €., mainly due to decreased NE costs  CONCLUSIONS: lipegfilgatrim is cost-saving compared with pegfilgrastim. These savings are confirmed across a wide range of input values.